CIK 0001815776 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
LENZ Therapeutics, Inc.
Sign in to watch- Ticker
- LENZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844867570
- Phone
- 858-925-7000
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Former names
- Graphite Bio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,134,778
- in 1 filing
Net −$9,134,778. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-21 | Odrich Marc Chief Medical Officer | Grant or award · Stock Option (right to buy) | +66,472 | 66,472 | ||
| 2024-03-21 | Odrich Marc Chief Medical Officer | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2024-03-21 | Schimmelpennink Evert B. President, CEO and Secretary | Grant or award · Stock Option (right to buy) | +387,106 | 387,106 | ||
| 2024-03-21 | Schimmelpennink Evert B. President, CEO and Secretary | Grant or award · Stock Option (right to buy) | +82,723 | 82,723 | ||
| 2024-03-21 | Schimmelpennink Evert B. President, CEO and Secretary | Grant or award · Stock Option (right to buy) | +315,864 | 315,864 | ||
| 2024-03-21 | Schimmelpennink Evert B. President, CEO and Secretary | Grant or award · Stock Option (right to buy) | +475,000 | 475,000 | ||
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award | +2,386,301 | 2,386,301 | ||
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award | +694,755 | 694,755 | ||
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award | +164,729 | 164,729 | ||
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +933,038 | $15.03 | $14.0M | 3,319,339 |
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +64,971 | $15.03 | $977K | 694,755 |
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Warrants (Right to Buy) | +54,582 | 54,582 | ||
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Warrants (Right to Buy) | +10,580 | 10,580 | ||
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Warrants (Right to Buy) | +5,371 | 5,371 | ||
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-03-21 | Scheiner Zachary Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-03-21 | Versant Venture Capital VI, L.P. 10% owner | Other acquisition | +598,203 | 842,162 | ||
| 2023-07-28 | Drapkin Kimberlee C Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2023-07-19 | Viney Joanne L. Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2023-07-19 | Porteus Matthew Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 |
Page 6 of 11 · 217 trades